ADMA shares have climbed 13.8% over the past three months, largely fueled by robust demand for its flagship immunoglobulin product, Asceniv. Quarterly shipment volumes jumped 25% year-over-year, with hospital and clinic orders rising to 18,000 vials in Q4 from 14,400 vials a year earlier. This volume surge contributed to a 22% increase in product revenues during the period, underscoring growing market penetration in both primary immunodeficiency and vaccine-enhancement applications.

Following the recent performance, management raised its full-year 2026 revenue projection to $165 million, up from the prior target of $140 million, reflecting improved dosing frequency and expanded distribution agreements in Europe and North America. EBITDA guidance for 2026 was also lifted to $50 million from $38 million, driven by scale economies and an anticipated gross margin expansion to approximately 52%, compared with 45% in the current fiscal year.

In the latest trading session, ADMA shares advanced by 1.62% on above-average volume. Trading activity totaled 1.2 million shares, marking a 40% increase over the 30-day daily average. Analyst coverage has intensified, with two brokerages raising their ratings to “outperform” and setting higher target ranges for the remainder of 2025, reflecting confidence in sustained product uptake and pipeline progress.